Buy-backs when news isn't bad

Getting back a product previously licensed to a larger partner can pose challenges to a biotech company, which often must prove to the outside world that there are valid reasons to continue development. Last week, BioCentury looked at the most difficult cases - those where there was negative data. In those situations, there's nothing to do except produce new, better data.

But many times the product is not the issue. Changing priorities at the partner, often experienced as a slower development schedule or less aggressive marketing effort than the smaller party desires, can result in the project being sent back home. ...